

1 Original article

2 **The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens:**
3 **Safety and immunogenicity to Omicron BA.4/BA.5**

4 Sitthichai Kanokudom^{a,b}, Jira Chansaenroj^a, Nungruthai Suntronwong^a, Suvichada Assawakosri
5^{a,b}, Ritthideach Yorsaeng^a, Pornjarim Nilyanimit^a, Ratchadawan Aeemjinda^a, Nongkanok
6 Khanarat^a, Preeyaporn Vichaiwattana^a, Sirapa Klinfueng^a, Thanunrat Thongmee^a, Donchida
7 Srimuan^a, Thaksaporn Thatsanatorn^a, Natthinee Sudhinaraset^a, Nasamon Wanlapakorn^a,
8 Sittisak Honsawek^{b,*}, and Yong Poovorawan^{a,c,*}

9^a Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,
10 Bangkok, 10330, Thailand.

11^b Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine,
12 Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society,
13 Bangkok, 10330, Thailand.

14^c Fellow of the Royal Society of Thailand (FRS [T]), the Royal Society of Thailand, Sanam
15 Sueapa, Dusit, Bangkok, 10300, Thailand.

16

17 **Corresponding authors:** Sittisak Honsawek (sittisak.h@chula.ac.th) and Yong Poovorawan
18 (yong.p@chula.ac.th)

19

20 Running head: Fourth dose COVID-19 mRNA vaccine after different three-dose regimens

21

22 **Abstract**

23 **Objective:** To investigate the reactogenicity and immunogenicity of the fourth dose using
24 mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50
25 µg mRNA-1273 vaccines.

26 **Methods:** This prospective cohort study was conducted between June and October 2022. The
27 self-recorded reactogenicity was evaluated on the subsequent 7 days after a fourth dose. Binding
28 and neutralizing activity of antibodies against the Omicron BA.4/5 variants were determined.

29 **Results:** Overall, 292 healthy adults were enrolled and received BNT162b2 or mRNA-1273.
30 Reactogenicity was mild to moderate and well-tolerated after a few days. Sixty-five individuals
31 were excluded. Thus, 227 eligible individuals received a fourth booster dose of BNT162b2
32 (n=109) and mRNA-1273 (n=118). Most participants, regardless the type of previous three dose
33 regimens, elicited a significantly high level of binding antibodies and neutralizing activity
34 against the Omicron BA.4/5 28 days after a fourth dose. The neutralizing activity against the
35 Omicron BA.4/5 between the BNT162b2 (82.8%) and mRNA-1273 (84.2%) groups was
36 comparable with a median ratio of 1.02.

37 **Conclusion:** This study found that the BNT162b2 and mRNA-1273 vaccines can be used as a
38 fourth booster dose for individuals who were previously immunized with any prior mix and
39 match three dose COVID-19 vaccine.

40 **Keywords:** Severe acute respiratory virus 2 (SARS-CoV-2); Omicron; safety; immunogenicity;
41 mRNA vaccine; Booster dose

42

43 **1. Introduction**

44 Coronavirus disease 2019 (COVID-19) is a flu-like disease caused by severe acute
45 respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 has rapidly evolved across
46 the world. Since the first identification of the Omicron variant in South Africa on 26 November
47 2021, several subvariants have been identified (Shrestha et al., 2022). The Omicron lineages
48 have caused outbreaks of COVID-19 in multiple countries around the world from early 2022 to
49 date (Tegally et al., 2022). On 6 January 2023, there were more than 667 million confirmed cases
50 worldwide with 4.7 million cases in Thailand, and 6.7 million reported deaths worldwide and
51 over 33,000 deaths in Thailand alone (Worldmeter, 2023).

52 In many countries, including Thailand, most initial vaccinations were administered
53 with two doses of inactivated vaccine (CoronaVac or BBIBP-CorV), two doses of viral vector
54 vaccine (AZD1222) or a heterologous schedule (CoronaVac followed by AZD1222) to ensure
55 adequate coverage. After the arrival of BNT162b2 and mRNA-1273 in Thailand and the spread
56 of the Delta variant SARS-CoV-2 in July 2021, the Ministry of Public Health recommended a
57 third dose vaccination campaign with AZD1222, BNT162b2, and mRNA-1273 administered
58 after three months of second dose vaccination. Subsequently, a fourth dose was offered on 21
59 March 2022, to combat the newly emerging Omicron variant, which evades pre-existing vaccine-
60 induced immunity (Magen et al., 2022). On 2 December 2022, more than 26 million individuals
61 (38.5%) of the Thai population had received three doses and approximately 5.8 million (8.4%)
62 had received four doses (Thai-DDC, 2023). Limited safety and immunogenicity studies are
63 currently available evaluating the fourth dose vaccination after three-dose mix-and-match
64 vaccinations.

65 The third booster dose elicits a high immune response against infection (Akaishi et
66 al., 2022; Wan et al., 2022). A field study demonstrated that the third dose increased vaccine
67 effectiveness against disease severity (Accorsi et al., 2022, Favresse et al., 2022), and reduced
68 hospitalization rates (Adams et al., 2022, Wan et al., 2022). Furthermore, a third dose vaccine
69 increases neutralizing capacity against the Omicron variant in laboratory tests (Assawakosri et
70 al., 2022a, Assawakosri et al., 2022b, Kanokudom et al., 2022a, Kanokudom et al., 2022b,
71 Suntronwong et al., 2022b). Waning immunity after three doses appears to significantly reduce
72 vaccine efficacy (VE) against infection at 3–6 months of follow-up (Favresse et al., 2022), and
73 probably leads to breakthrough infections with the Delta/Omicron variants (Amanatidou et al.,
74 2022). Recent studies have shown that a fourth dose of mRNA vaccine was associated with a
75 reduced rate of symptomatic infection during the Omicron predominant period (Bar-On et al.,
76 2022; Regev-Yochay et al., 2022). According to a cohort study of individuals aged 80 and older
77 in Sweden, a fourth mRNA booster dose increased VE against mortality during the Omicron era
78 compared to three doses of BNT162b2 (Nordström et al., 2022). Additionally, a previous report
79 showed that the fourth dose reduced the infection rate and severity (Cohen et al., 2022).
80 Furthermore, surveillance of a total of 36,170 subjects in Northern Thailand indicated that VE
81 against Omicron infection of the subjects receiving a fourth dose was 75%, followed by the three
82 doses (VE of 31%), and one or two doses conferred little to no protection, respectively)
83 (Intawong et al., 2022). However, the clinical outcomes of a fourth booster dose after different
84 three-dose regimes remain unclear.

85 Many individuals require a booster dose to restore binding and neutralizing
86 antibodies that are no longer sufficient to combat the emerging Omicron subvariants. This study
87 investigated the increased effects of the fourth dose of mRNA vaccines, BNT162b2 and mRNA-

88 1273, after three mix and match dose regimens. In addition, we compared the reactogenicity and
89 immunogenicity among these two booster groups. This study provides important data to help
90 guide policy makers on the use of fourth doses of COVID-19 vaccines among the adult
91 population in Thailand.

92

93 **2. Materials and methods**

94 **2.1 Study designs and participant enrolment**

95 The cohort study was conducted between June and October 2022 at the Center for
96 Excellence in Clinical Virology, Chulalongkorn University, Bangkok. The study protocol was
97 approved by the Institutional Review Board (IRB) of the Faculty of Medicine of Chulalongkorn
98 University (IRB 223/65) and was conducted in accordance with the principles of the Declaration
99 of Helsinki. This trial was registered in the Thai Registry of Clinical Trials (TCTR
100 20210910002). Written informed consent was obtained from the participants before enrollment.

101 A total of 292 healthy adults 18 years and older, who had previously been
102 immunized with any of the three available doses of the COVID-19 vaccine for at least 3 months,
103 were enrolled. The cohort was stratified into 12 groups according to their primary three doses
104 (**Figure 1**). Participants with no history of COVID-19 disease received a fourth booster dose of
105 30 µg BNT162b2 or 50 µg mRNA-1273. Exclusion criteria were characteristics associated with
106 serious medical conditions and individuals who had pre-existing immunoglobulin (Ig) G specific
107 to nucleoprotein (N) (anti-N IgG), anti-N IgG seroconversion (negative to positive) and
108 confirmed positive tests to SARS-CoV-2.

109 **2.2 Vaccines**

110 The BNT162b (Pfizer-BioNTech Inc., New York City, NY, USA) vaccine contains
111 30 µg of mRNA encoding the SARS-CoV-2 spike protein (S) (Polack et al., 2020). The mRNA-
112 1273 (Moderna Inc., Cambridge, MA, USA) contains 50 µg of mRNA encoding SARS-CoV-2 S
113 protein, of which the half dose concentration has recently been recommended by the World
114 Health Organization Strategic Advisory Group of Experts on Immunization (SAGE) as a booster
115 dose for individuals aged 12 and older (Jackson et al., 2020, WHO, 2022). A dose of vaccine was
116 administered intramuscularly.

117 **2.3 Safety assessments**

118 The enrolled participants self-reported reactogenicity using an electronic or paper
119 questionnaire, starting on the day of vaccination and for 7 subsequent days (days 0–7). Local,
120 systemic and adverse events (AE) were classified as mild, moderate and severe, as previously
121 described (Kanokudom et al., 2022a).

122 **2.4. Laboratory assessments**

123 Serum samples were collected to determine binding antibody responses, including
124 total immunoglobulin (Ig) anti-RBD of the SARS-CoV-2 spike protein (total RBD Ig) using the
125 Elecsys SARS-CoV-2 S electrochemiluminescence immunoassay (ECLIA) according to the
126 manufacturer's instructions (Roche Diagnostics, Basel, Switzerland), the anti-RBD IgG using a
127 Quant chemiluminescent microparticle immunoassay (CMIA) (Abbott Laboratories, Abbott
128 Park, IL, USA), and anti-N IgG using CMIA (Abbott Diagnostics, Sligo, Ireland) as previously
129 described (Kanokudom et al., 2022a). Neutralizing activity against the SARS-CoV-2 Spike
130 protein RBD-HRP Omicron (BA.4/BA.5) (hereafter referred to as BA.4/5) (G339D, S371F,
131 S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A,
132 F486V, Q498R, N501Y, Y505H) (GenScript Biotech, Piscataway, NJ, USA) was analyzed using

133 a surrogate virus neutralization test (sVNT) as previously described (Assawakosri et al., 2022b,
134 Wanlapakorn N. et al., 2022b). Seropositivity of sVNT against Omicron (BA.4/5) was defined as
135 $\geq 30\%$ inhibition, respectively.

136 **2.5. Statistical analysis**

137 Baseline characteristics were reported as mean with standard deviation (SD) or
138 median with interquartile range (IQR). Categorical age and sex analyses were performed using
139 Pearson's Chi-square test. The difference in incidence of an adverse event after the fourth dose
140 with BNT162b2 or mRNA-1273 was analyzed using a risk difference (RD) with a 95%
141 confidence interval (CI). Total RBD Ig and anti-RBD IgG were designated as geometric mean
142 titers (GMT) with a 95% CI. The percentage inhibition using sVNT was presented as median
143 with interquartile range (IQR) values. The geometric mean ratio (GMR) of total-RBD Ig and
144 anti-RBD IgG was calculated using the Mann–Whitney *U* test. Significant differences between
145 the two groups in antibody titers and percentage inhibition were compared using the Mann–
146 Whitney *U* test. Non-parametric correlation between the GMT of total RBD Ig or anti-RBD IgG
147 and the percent inhibition was calculated using Spearman's rank correlation coefficient
148 (Spearman's ρ). The linear equation and coefficient of determination (r-square, R^2) between the
149 transformation of the logarithmic GMT of total-RBD Ig or anti-RBD IgG and percent inhibition
150 was calculated based on a simple linear regression model. A p -value <0.05 was considered
151 statistically significant.

152

153

154

155 **3. Results**

156 **3.1 Demographic data and baseline characteristics**

157 Between June and October 2022, a total of 292 healthy individuals from 12 different
158 three-dose regimes (provided in **Figure 1**) were enrolled to receive a fourth booster dose of
159 BNT162b2 or mRNA-1273. Sixty-five individuals were excluded and consisted of 24 subjects
160 with pre-existing anti-N IgG, 8 subjects with anti-N IgG seroconversion from negative to
161 positive, and 33 cases lost to follow-up. After exclusions, 227 individuals remained and were
162 divided in two booster dose groups: BNT162b2 (n=109) and mRNA-1273 (n=118).

163 The demographics and characteristics of the eligible participants who received
164 BNT162b2 or mRNA-1273, including sex, age, comorbidity, the time interval between the third
165 and fourth dose, and the time interval between the fourth dose and blood collection (28 ± 7 days)
166 are shown in **Table 1**. The number of females (%) in the BNT162b2 and mRNA-1273 groups
167 was 66.1% and 60.2%, respectively. The mean age of the BNT162b and mRNA-1273 groups
168 was 48.8 and 48.2 years, respectively. There were no significant differences in terms of sex and
169 age between the groups. The median interval between the third and fourth doses of BNT162b2
170 (191.0 days) was significantly shorter than that of the mRNA-1273 group (210.5 days).

171 **3.2 Local and systemic adverse events resolved after receiving the mRNA-COVID-19** 172 **vaccine as the fourth booster dose**

173 Profiles of local and systemic reactions within 7 days after vaccination with BNT162b2 and
174 mRNA-1273 in each regimen included injection site pain, myalgia, and swelling
175 (**Supplementary Figure S1A–L**). The safety profile of healthy participants who received a
176 booster dose of BNT162b2 (n=139) or mRNA-1273 (n=150) was defined using a self-
177 questionnaire. The most frequent adverse events were mild to moderate injection site pain

178 (77.0% vs. 81.3%), followed by myalgia (63.3% vs. 62.0%), and swelling (39.6% vs. 54.0%) for
179 the BNT162b2 and mRNA-1273 groups, respectively (**Figure 2A,B**). Furthermore, other adverse
180 events observed in both groups were well tolerated and resolved in a few days. To compare the
181 incidence between the two booster groups, swelling (RD: 14.4, 95%CI: 3.0–25.8), fever (RD:
182 4.0, 95%CI: 0.9–7.1) and headache (RD: 11.2, 95%CI: 0.4–22.1) were more frequent in the
183 mRNA-1273 group than in the BNT162b2 group (**Figure 2C**).

184 **3.3 Total-RBD Ig and anti-RBD IgG responses of eligible participants**

185 A total of 227 individuals were seronegative anti-N IgG (no history of SARS-CoV-2
186 infection) and further examined for binding antibodies levels, including total RBD Ig and anti-
187 RBD IgG. At baseline, the GMT of the total RBD Ig between 12 regimens ranged from 480.4 to
188 3112 U/mL. At 28 days after the fourth dose, all eligible individuals achieved a GMT of the total
189 RBD Ig ranging from 11,992 to 32,003 U/mL (**Supplementary Figure S1A**). Furthermore, the
190 GMT for the baseline anti-RBD IgG among all eligible individuals of the 12 regimens ranged
191 from 77.9 to 492.2 BAU/mL. After the booster dose, the GMT of anti-RBD IgG for the 12
192 groups increased between 1562 and 4664 BAU/mL (**Supplementary Figure S1B**). Although
193 individuals had several three-dose schedules, the fourth dose generated a higher antibody titer
194 specific for SARS-CoV-2 RBD for all regimens at 28 days.

195 To compare immunogenicity resulting from the fourth dose, sera samples were
196 collected for the two groups according to the booster dose of BNT162b (n=109) and mRNA-
197 1273 (n=118). The baseline total RBD Ig GMT between the BNT162b2 and mRNA-1273 groups
198 was similar (GMR: 0.93). After 28 days, the total RBD Ig GMT of the mRNA-1273 group was
199 significantly higher than that of the BNT162b2 group (GMR: 1.17, $p<0.05$) (**Figure 3A**).

200 Similarly, the anti-RBD IgG response trends at baseline and after 28 days of receiving a fourth
201 dose were consistent with the total RBD Ig response (**Figure 3B**).

202 **3.4 Neutralizing activity against Omicron BA.4/5 using sVNT₅₀**

203 A subset of participants who received a fourth dose of BNT162b2 (n=67) and
204 mRNA-1273 (n=93) was randomly selected for testing neutralizing activities against SARS-
205 CoV-2 Omicron BA.4/5 using sVNT₅₀. At baseline, the seronegativity (at threshold<30%)
206 against Omicron BA.4/5 was 19/67 (28.4%) for BNT162b2 and 33/93 (35.5%) for the mRNA-
207 1273 groups. The median baseline neutralizing activity was 41.8% (IQR: 26.2–49.8%) for
208 BNT162b2 and 35.9% (IQR: 22.0–50.2%) for the mRNA-1273 groups (**Figure 4**).

209 The neutralizing activity of boosted individuals receiving BNT162b2 and mRNA-
210 1273 was significantly restored to 82.8% ($p<0.001$) and 84.2% ($p<0.001$) at 28 days,
211 respectively. Furthermore, the median percentage inhibition against Omicron BA.4/5 between
212 the BNT162b2 and mRNA-1273 groups was comparable to baselines (median ratio: 0.86) and
213 after receiving a booster dose (median ratio: 1.02) (**Figure 4**).

214 **3.5 Correlations between binding antibody and neutralizing activity against Omicron** 215 **BA.4/5**

216 To substantially assess the correlation between binding antibody and neutralizing
217 activity against Omicron BA.4/5, a total of 320 sera were randomly selected from individual
218 samples before (day 0) and after (day 28) receiving BNT162b2 or mRNA-1273. Quantitative
219 ELISA levels of total RBD Ig and anti-RBD IgG, and *in vitro* ACE2-RBD binding neutralizing
220 activity, which measured sVNT₅₀, were further examined to determine the correlation between
221 techniques. The percent inhibition for the Omicron BA.4/5 ranged from 0.0% (undetectable) to
222 99.6% compared to total RBD-Ig and anti-RBD IgG, respectively. The non-parametric

223 correlation indicated that the percent inhibition against the Omicron BA.4/5 subvariant was
224 strongly correlated with total RBD Ig (Spearman's ρ : 0.83, $p < 0.001$). A linear regression
225 equation showing the percent inhibition against Omicron BA.4/5 based on \log_{10} (total RBD Ig) is
226 presented in **Supplementary Figure 3A** (R^2 : 0.70). The correlation between the percent
227 inhibition against the Omicron BA.4/5 and anti-RBD IgG showed a similar trend as total-RBD Ig
228 (Spearman's ρ : 0.82, $p < 0.001$ and R^2 : 0.68) (**Supplementary Figure 3B**).

229 **4. Discussion**

230 We compared the reactogenicity of BNT162b2 and half-dose mRNA-1273 resulting
231 from the administration of a fourth booster dose in healthy adults who had previously received
232 different vaccine schedules. These findings revealed that common side effects were injection site
233 pain, myalgia, headache, swelling, and redness at the injection site, which was in agreement with
234 previous studies evaluating the application of mRNA vaccines as the third (Kanokudom et al.,
235 2022a, Munro et al., 2021) and the fourth (Munro et al., 2022) doses.

236 This study evaluated the binding antibody targeting the SARS-CoV-2 spike protein
237 in terms of total RBD Ig and anti-RBD IgG. For individuals who had received the third dose for
238 approximately 3–12 months (min–max: 94–371 days), binding antibody levels were notably low.
239 The present study showed that a fourth dose with the mRNA vaccine could restore the total RBD
240 Ig titer from 11,992 to 32,003 U/mL among all regimens. Comparison of the two boosted groups
241 showed that half-dose mRNA-1273 (50 μ g) could induce a slightly higher response than in those
242 immunized with BNT162b2 (30 μ g). This evidence was possibly due to a dose-dependent
243 response of active RNA molecules, as demonstrated previously (Kanokudom et al., 2022a). The
244 GMT of total RBD Ig among 12 groups was varied due to abundant factors consisting of time
245 intervals between the previous dose and the last dose, the vaccination dose, and the primary

246 regimens. Additionally, in agreement with a previous study by Wanlapakorn et al. (2022), the
247 present study indicated that individuals who were primed with an inactivated vaccine followed
248 by an mRNA vaccine showed stronger immunogenicity compared to individuals who were
249 primed with a viral vector or heterologous inactivated/viral vector vaccination schedule

250 In the present study, the boosted neutralizing activity against the variant Omicron
251 BA.4/5 after the fourth dose with the BNT162b2 and mRNA-1273 was observed on day 28. Our
252 finding was in agreement with that of a previous study showing that there was no significant
253 difference between BNT162b2 and mRNA-1273 in neutralizing activity against the Omicron
254 variant (Wan et al., 2022). A fourth dose of BNT162b2 may increase the effectiveness of the
255 vaccine against severe diseases compared to three doses (Magen et al., 2022). The fourth dose of
256 BNT162b2 and mRNA-1273 subsequent to any three-dose regimen used in this study was
257 expected to achieve a similar response to severe illness.

258 Our study evaluated the correlation between anti-RBD antibodies determined by two
259 routine quantitative ELISA methods (expressed in total RBD Ig or anti-RBD IgG) and
260 neutralizing activity determined by sVNT (expressed in percent inhibition of ACE2-RBD
261 binding). Although two routine ELISA kits measured antibody titers against Wuhan-RBD and
262 sVNT measured neutralizing antibody levels against Omicron BA.4/5, a strong correlation
263 between the routine ELISA findings and sVNT was observed. Furthermore, our previous study
264 evaluating different three-dose vaccinations showed a correlation between sVNT and the gold
265 standard live virus neutralization test also called the foci-reduction neutralization test (FRNT₅₀)
266 against Omicron BA.1 and BA.2 (Spearman's ρ : 0.77 and 0.64, respectively) (Suntronwong et
267 al., 2022a). These data might suggest that the commercial sVNT assay was a suitable alternative
268 to the conventional neutralization test.

269 The current findings demonstrated that boosted individuals with either mRNA
270 vaccine could achieve a high level of binding antibody and neutralizing activity regardless of the
271 primary three-dose vaccine regimens. Our findings were consistent with the VE study that
272 showed that four-doses increased VE against Omicron infection compared to the three-doses or
273 less (Intawong et al., 2022). In summary, these findings provide evidence for recommending the
274 use of the mRNA vaccine as a fourth dose in healthy adults who completed three doses of mix-
275 and-match as primary regimens.

276 This study was subject to certain limitations. It was challenging to find COVID-19
277 naïve participants that had avoided multiple COVID-19 waves. Approximately 20% of the
278 participants were excluded due to a suspected history of COVID-19 or were lost follow-up.
279 Long-term immunity and durability of immune responses after a fourth booster dose should be
280 further determined. Additional studies on VE against infection and disease severity should be
281 conducted to verify the findings.

282 **5. Conclusions**

283 This study found no significant difference in neutralizing activities against Omicron
284 BA.4/5 among sera of individuals receiving either the BNT162b2 or mRNA-1273 vaccine as a
285 fourth dose. The two routine ELISA methods, used to test total RBD Ig and anti-RBD IgG, could
286 quantitatively predict neutralizing activity against Omicron BA.4/5. Overall, this study suggests
287 that BNT162b2 and mRNA-1273 could be used as booster doses after different three-dose
288 regimens.

289 **Acknowledgments:** We would like to thank all Center of Excellence in Clinical Virology
290 personnel and all participants for contributing to and supporting this project. This research was
291 financially supported by the Health Systems Research Institute (HSRI), National Research

292 Council of Thailand (NRCT), MK restaurant Group Aunt Thongkum Foundation, BJC Big C
293 Foundation, the Center of Excellence in Clinical Virology, Chulalongkorn University, and King
294 Chulalongkorn Memorial Hospital, and was partially supported by the Second Century Fund
295 (C2F) of Sitthichai Kanokudom, Chulalongkorn University.

296 **Author Contributions:** Conceptualization, S.K. (Sitthichai Kanokudom), P.N., S.H., and Y.P.;
297 data curation, S.K. (Sitthichai Kanokudom), R.Y., N.S. (Nungruthai Suntronwong), S.A., D.S.,
298 T.T. (Thaksaporn Thatsanatorn), N.S. (Natthinee Sudhinaraset) and N.W.; formal analysis, S.K.
299 (Sitthichai Kanokudom); methodology, S.K. (Sitthichai Kanokudom), J.C., R.A., N.K., P.V.,
300 S.K. (Sirapa Klinfueng) and T.T (Thanunrat Thongmee); project administration, Y.P.; writing—
301 original draft, S.K. (Sitthichai Kanokudom); writing—review and editing, S.K. (Sitthichai
302 Kanokudom), S.H. and Y.P. All authors have read and agreed to the published version of the
303 manuscript.

304 **Funding:** This study was financially supported by the Health Systems Research Institute
305 (HSRI), National Research Council of Thailand (NRCT), MK restaurant Group Aunt Thongkum
306 Foundation, BJC Big C Foundation, the Center of Excellence in Clinical Virology,
307 Chulalongkorn University, and King Chulalongkorn Memorial Hospital, and partially supported
308 by the Second Century Fund (C2F) of Sitthichai Kanokudom, Chulalongkorn University.

309 **Institutional Review Board Statement:** The study protocol was approved by the Institutional
310 Review Board (IRB), Faculty of Medicine, Chulalongkorn University (IRB number 223/65).

311 **Informed Consent Statement:** Informed consent was obtained before participant enrollment.
312 The study was conducted according to the Declaration of Helsinki and the Good Clinical Practice
313 Guidelines (ICH-GCP) principles.

314 **Data Availability Statement:** The datasets generated and analyzed during the current study are
315 available from the corresponding author upon reasonable request.

316 **Conflicts of Interest:** The authors declare no conflict of interest.

317 **References**

318 Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association
319 between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by
320 the SARS-CoV-2 Omicron and Delta variants. *JAMA* 2022;327:639–51.

321 Adams K, Rhoads JP, Surie D, Gaglani M, Ginde AA, McNeal T, et al. Vaccine effectiveness of
322 primary series and booster doses against COVID-19 associated hospital admissions
323 in the United States: living test negative design study. *BMJ* 2022;379:e072065.

324 Akaishi T, Kushimoto S, Katori Y, Sugawara N, Egusa H, Igarashi K, et al. Effectiveness of
325 third vaccine dose for Coronavirus disease 2019 during the Omicron variant
326 pandemic: a prospective observational study in Japan. *Sci Rep* 2022;12:13589.

327 Amanatidou E, Gkiouliava A, Pella E, Serafidi M, Tsilingiris D, Vallianou NG, et al.
328 Breakthrough infections after COVID-19 vaccination: insights, perspectives and
329 challenges. *Metabolism Open* 2022;14:100180.

330 Assawakosri S, Kanokudom S, Chansaenroj J, Suntronwong N, Auphimai C, Nilyanimit P, et al.
331 Persistence of immunity against Omicron BA.1 and BA.2 following homologous and
332 heterologous COVID-19 booster vaccines in healthy adults after a two-doses
333 AZD1222 vaccination. *Int J Infect Dis* 2022a;122:793–801.

334 Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et
335 al. Neutralizing activities against the Omicron variant after a heterologous booster in
336 healthy adults receiving two doses of CoronaVac vaccination. *J Infect Dis* 2022b.

- 337 Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al. Protection by
338 a fourth dose of BNT162b2 against Omicron in Israel. *N Engl J Med*
339 2022;386:1712–20.
- 340 Cohen MJ, Oster Y, Moses AE, Spitzer A, Benenson S, Group I-HtVW. Association of receiving
341 a fourth dose of the BNT162b vaccine with SARS-CoV-2 infection among health
342 care workers in Israel. *JAMA Netw Open* 2022;5:e2224657-e.
- 343 Favresse J, Gillot C, Bayart J-L, David C, Simon G, Wauthier L, et al. Vaccine-induced binding
344 and neutralizing antibodies against Omicron 6 months after a homologous
345 BNT162b2 booster. *J Med Virol* 2022;95:e28164.
- 346 Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W,
347 Thongprachum A, et al. Effectiveness of heterologous third and fourth dose COVID-
348 19 vaccine schedules for SARS-CoV-2 infection during delta and omicron
349 predominance in Thailand: A test-negative, case-control study. *Lancet Reg Health*
350 Southeast Asia 2022; 100121. Available from: [https:](https://doi.org/10.1016/j.lansea.2022.100121)
351 [doi:10.1016/j.lansea.2022.100121](https://doi.org/10.1016/j.lansea.2022.100121)
- 352 Jackson LA, Anderson EJ, Roupael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA
353 vaccine against SARS-CoV-2 - preliminary report. *N Engl J Med* 2020;383:1920–31.
- 354 Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, et al.
355 Comparison of the reactogenicity and immunogenicity of a reduced and standard
356 booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of
357 inactivated vaccine. *Vaccine* 2022a;40:5657–63.
- 358 Kanokudom S, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, et al.
359 Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine

360 (CovovaxTM) after homologous and heterologous two-dose regimens. *Int J Infect*
361 *Dis* 2022b;126:64–72.

362 Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, et al. Fourth dose of
363 BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. *N Engl J Med*
364 2022;386:1603–14.

365 Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety, immunogenicity,
366 and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as
367 fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a
368 third dose of BNT162b2 (COV-BOOST): A multicentre, blinded, phase 2,
369 randomised trial. *Lancet Infect Dis* 2022;22:1131–41.

370 Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and
371 immunogenicity of seven COVID-19 vaccines as a third dose (booster) following
372 two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a
373 blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet* 2021;398:2258–
374 76.

375 Nordström P, Ballin M, Nordström A. Effectiveness of a fourth dose of mRNA COVID-19
376 vaccine against all-cause mortality in long-term care facility residents and in the
377 oldest old: A nationwide, retrospective cohort study in Sweden. *Lancet Reg Health*
378 *Eur* 2022;21:100466.

379 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy
380 of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020;383(27):2603–15.

- 381 Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy of
382 a fourth dose of Covid-19 mRNA vaccine against Omicron. *N Engl J Med*
383 2022;386:1377–80.
- 384 Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2
385 Omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
386 *Rev Med Virol* 2022;32:e2381.
- 387 Suntronwong N, Assawakosri S, Kanokudom S, Yorsaeng R, Auphimai C, Thongmee T, et al.
388 Strong correlations between the binding antibodies against wild-type and neutralizing
389 antibodies against Omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals
390 following booster (third-dose) vaccination. *Diagnostics* 2022a;12:1781.
- 391 Suntronwong N, Kanokudom S, Auphimai C, Assawakosri S, Thongmee T, Vichaiwattana P, et
392 al. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses
393 to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222
394 vaccination. *J Med Virol* 2022b;94:5713–22.
- 395 Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Emergence of
396 SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. *Nat Med*
397 2022;28:1785–90.
- 398 Thailand Department of Disease Control (Thai-DDC). COVID-19 vaccine in Thailand.; 2023.
399 Available from: [https://ddc.moph.go.th/vaccine-](https://ddc.moph.go.th/vaccine-covid19/getFiles/7/1670402801471.jpg)
400 [covid19/getFiles/7/1670402801471.jpg](https://ddc.moph.go.th/vaccine-covid19/getFiles/7/1670402801471.jpg) [Accessed 6 January 2023].
- 401 Wan EYF, Mok AHY, Yan VKC, Wang B, Zhang R, Hong SN, et al. Vaccine effectiveness of
402 BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection,

403 hospitalisation, severe complications, cardiovascular disease and mortality in patients
404 with diabetes mellitus: A case control study. *J Infect* 2022;85:e140-e4.

405 Wanlapakorn N, Suntronwong N, Kanokudom S, Assawakosri S, Nilyanimit P, Yorsaeng R, et
406 al. Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster)
407 following two doses of different primary series regimens in Thailand. *Pathog Glob*
408 *Health* 2022;116:395–7.

409 The WHO Strategic Advisory Group of Experts on Immunization (SAGE). The Moderna
410 COVID-19 (mRNA-1273) vaccine: what you need to know.; 2022. Available from:
411 [https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-](https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know)
412 [1273-vaccine-what-you-need-to-know](https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know). [Accessed 18 August 2022].

413 Worldmeter. COVID-19 Coronavirus pandemic.; 2023. Available from:
414 <https://www.worldometers.info/coronavirus/> [Accessed 9 January 2023].


415

416 **Figures and Tables**

417 **Table 1. Characteristics of the individuals who received a fourth booster COVID-19**
 418 **vaccine.**

Characteristic	BNT162b2	mRNA-1273
Number	109	118
Sex, female n (%)	72 (66.1)	71 (60.2)
Age, years, mean [SD] (min–max)	48.8 [11.5] (20.0–73.0)	48.2 [11.8] (23.0–74.0)
No comorbidity (%)	68 (62.4)	86 (72.9)
Underlying diseases (%)		
Allergy	5 (4.6)	5 (4.2)
Dyslipidemia	12 (11.0)	11 (9.3)
Diabetes Mellitus	4 (3.7)	4 (3.4)
Hypertension	11 (10.1)	15 (12.7)
Thyroid	2 (1.8)	2 (1.7)
Others	10 (9.2)	4 (3.4)
Interval between the 3 rd and 4 th dose (days)		
Median [IQR] (min–max)	191.0 [163.0–223.0] (94.0–337.0)	210.5 [177.0–224.3] (117.0–371.0)
Interval between the 4 th dose and blood collection (days)		
Median [IQR] (min–max)	28.0 [28.0–29.0] (22.0–32.0)	28.0 [28.0–32.0] (26.0–34.0)

419 Abbreviation: IQR, interquartile range; SD, standard deviation.



420

421 **Figure 1. Study flow diagram of participants enrolled and collection of eligible samples.**

422 Individuals (18 years and older), who had previously been immunized with different three doses,

423 were assigned to receive the fourth booster dose with 30 µg BNT162b2 or 50 µg mRNA-1273.


424 Blood samples were collected on days 0 and 28 ± 7 after booster dose. Serum samples were

425 previously screened according to the level of anti-nucleoprotein (N) IgG. Participants who had
426 seropositive anti-N IgG (pre-existing and seroconversion) were excluded. The remaining
427 participants were eligible for the evaluation of immunogenicity analyses after booster
428 vaccination.


429 Abbreviations: AEs, adverse events; A and AZ, AZD1222; Ig, immunoglobulin; M and MN,
430 mRNA-1273; N, nucleoprotein; P and PF, BNT162b2; S, inactivated vaccine BBIBP-CorV (SP)
431 or CoronaVac (SV).

432


A



B



C




433

434 **Figure 2. Overall reactogenicity of individuals who received a fourth dose of either**

435 **BNT162b2 or mRNA-1273.**

436 The percentages of local, systemic, and any adverse events (AE) experienced within 7 days of
437 receiving (A) BNT162b2 or (B) mRNA-1273. (C) Forest plots showing the incidences of each
438 AE and the risk differences with 95% confidence intervals (95% CI).

439




440

441 **Figure 3. Binding antibody against the receptor binding domain of SARS-CoV-2 of the**
 442 **BNT162b2 and mRNA-1273 booster groups.**

443 (A) Total immunoglobulin (Ig) specific for the receptor binding domain (RBD) (Total RBD Ig)
 444 (U/mL) and (B) anti-RBD IgG (BAU/mL) of the BNT162b2 and mRNA-1273 booster groups
 445 were monitored at baseline (D0) and 28 days after vaccination (D28). The gray area indicates the
 446 seronegativity of total RBD Ig (<0.8 U/mL) or anti-RBG IgG (<7.1 BAU/mL) antibodies. Lines
 447 represent the geometric mean titer (GMT) with 95% confidence intervals (95% CI). A pairwise
 448 comparison shows geometric mean ratio (GMR) and statistical significance set at $p < 0.05$ (*),
 449 $p < 0.001$ (**), and no statistical significance (ns).

450 Abbreviation: BAU, binding antibody unit; CI, confidence interval; D0, day 0; D28, day 28;
 451 GMT, geometric mean titer; GMR, geometric mean ratio; Ig, immunoglobulin; ns, no statistical
 452 significance.

453



454

455 **Figure 4. Neutralizing activity of participants against the SARS-CoV-2 Omicron BA.4/5 at**

456 **28 days after the fourth dose.** Sera were obtained from a subset of individuals at baseline (D0)

457 and at 28 days (D28) after receiving a booster dose of BNT162b2 and mRNA-1273. The gray

458 area indicates the neutralizing activity of the SARS-CoV-2 Omicron BA.4/5 (<math><30\%</math>). Lines

459 represent the medians (%) with interquartile range (IQR) values. A pairwise comparison displays

460 the median ratio and the lack of statistical significance (ns).

461 Abbreviation: D0, day 0; D28, day 28; GMT, geometric mean titer; GMR, geometric mean ratio;

462 IQR; interquartile range; ns, no statistical significance.

463

464 **Supplementary materials**

465 **Figure S1. Solicited local, systemic, and adverse events of enrolled participants in different**
466 **regimens.** (A) SSAP, (B) SSAM, (C) SSPP, (D) SSMM, (E) AAAP, (F) AAAM, (G) AAPP, (H)
467 AAMM, (I) SAAP, (J) SAAM, (K) SAPP, and (L) SAMM groups and the proportion of mild,
468 moderate and severe adverse event 7 days after a booster dose for each group.

469 Abbreviations: A, AZD1222; M, mRNA-1273; P, BNT162b2; S, inactivated vaccine BBIBP-
470 CorV or CoronaVac.

471

472 **Figure S2. Binding antibody titers against the receptor binding domain of SARS-CoV-2 of**
473 **the 12 different four-dose regimens.** (A) Total immunoglobulin (Ig) specific for receptor
474 binding domain (RBD) (Total RBD Ig) (U/mL) and (B) anti-RBD IgG (BAU/mL) were assessed
475 for 12 different vaccine regimens on days 0 and 28 ± 7 . The X-axis indicates the code of
476 participant regimens, followed by the day of collection (0 and 28) The gray area indicates the
477 seronegativity of total RBD Ig (<0.8 U/mL) or anti-RBG IgG (<7.1 BAU/mL). Each column
478 shows a scatter plot with a geometric mean titer (GMT). The lines represent GMT with 95%
479 confidence intervals (95% CI). Parentheses indicate the number of individuals in each regimen.

480 Abbreviations: A, AZD1222; BAU, binding antibody unit; M, mRNA-1273; P, BNT162b2; S,
481 inactivated vaccine BBIBP-CorV or CoronaVac.

482

483 **Figure S3. Predicted linear correlation between the binding antibody and neutralizing**
484 **activity against Omicron BA.4/5 using the sVNT₅₀.** A total of 320 sera (at day 0 (n=160) and
485 day 28 (n=160)) from individuals who received a fourth dose of BNT162b2 and mRNA-1273

486 were tested for total RBD Ig and anti-RBD IgG levels and neutralizing activity against Omicron
487 BA.4/5 using sVNT₅₀. Linear regressions (solid line) showing the relationship between percent
488 inhibition against Omicron BA.4/5 and logarithm (\log_{10}) (Total RBD Ig) (A) or \log_{10} (Anti-RBD
489 IgG) (B). The linear equation and the r-square (R^2) were calculated according to a simple linear
490 regression model between the transformed \log_{10} of the binding antibody and the percentage of
491 inhibition. The dotted line indicates the seronegativity of neutralizing activity of SARS-CoV-2
492 Omicron BA.4/5 (<30%).

493 Abbreviations: BAU, binding antibody unit; Ig, immunoglobulin.

494